Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIVID: IL-6 Inhibitors in Severe COVID-19 Pneumonia
NCT04322773Phase 2Terminated
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab, sarilumab in COVID-19 pneumonia. Started Apr 2020; status: terminated.
02
Drugs
tocilizumabsarilumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04322773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322773.